To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: FDA Issues Approvable Letter for Bonefos (Clodronate) for Adjuvant Treatment of Breast Cancer URL: http://www.pslgroup.com/dg/248F7E.htm Doctor's Guide January 7, 2005
BERLIN, GERMANY -- January 7, 2005 -- Schering AG, Germany (FSE: SCH, NYSE: SHR) today announced that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for Bonefos® (clodronate), an oral non-amino bisphosphonate intended to reduce the occurrence of bone metastases in the post-surgical (adjuvant) treatment of breast cancer patients. Berlex, Inc., Schering's U.S. affiliate, plans to request a meeting with the FDA to discuss the information that is needed to obtain approval, and will submit this information as quickly as possible. "We look forward to the opportunity to meet with the FDA so we can advance the approval process," said Marc Rubin, MD, member of the Schering AG Board of Executive Directors responsible for Development and Oncology. This press release has been published by Corporate Communication of Schering AG, Berlin, Germany. SOURCE: Schering AG --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.